Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYB1904 in Adolescent Participants With Allergic Diseases
NCT07513857Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of ozureprubart in allergic disease, sponsored by Jemincare. Primary endpoints: Safety and Tolerability at 28 weeks and Pharmacokinetic profile of JYB1904 injection at 28 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
ozureprubart
03
Conditions
allergic disease
Beyond the preview
Go deeper on NCT07513857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513857.